Share Price | Sagimet Biosciences, Inc. Stock Analysis & Recommendation

Q: What does Sagimet Biosciences, Inc. do?

Overview: Sagimet Biosciences, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.Financial Snapshot: Net Profit: -18 Million (Quarterly Results - Mar 2025) Market Cap: USD 211.04 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.04 Return on Equity: -41.09% Price to Book: 1.52Contact Details: Details: No Company Details Available Registrar Address: Not available.

Q: Is Sagimet Biosciences, Inc. overvalued or undervalued?

As of 14 November 2024, the valuation grade for Sagimet Biosciences, Inc. has moved from risky to does not qualify, indicating significant concerns regarding its financial health. The company is currently considered overvalued given its negative performance metrics, including a price-to-book ratio of 1.23 and a return on equity (ROE) of -41.09%. Additionally, the EV to EBITDA and EV to EBIT ratios are both at -0.40, reflecting a troubling financial situation.In comparison to its peers, Sagimet's performance is starkly unfavorable. For instance, Fusion Pharmaceuticals, Inc. has a P/E ratio of -17.58, while Rigel Pharmaceuticals, Inc. stands out as very attractive with a P/E of 9.21. The recent stock performance of Sagimet, which has returned 142.32% over the past month, contrasts sharply with its valuation metrics, reinforcing the notion that it may be overvalued in the current market context.

Q: Is Sagimet Biosciences, Inc. technically bullish or bearish?

As of 1 August 2025, the technical trend for Sagimet Biosciences, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven primarily by the daily moving averages indicating mild bullishness. However, the weekly MACD and KST are mildly bearish, and the Bollinger Bands show a bearish signal on the weekly timeframe, which tempers the overall bullish outlook. The Dow Theory also reflects a mildly bearish stance on both weekly and monthly timeframes. In terms of performance, the stock has returned 50.0% year-to-date and 99.7% over the past year, significantly outperforming the S&P 500, which has returned 12.22% and 17.14% in the same periods, respectively.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

719.56 k

Shareholding (Sep 2025)

FII

7.09%

Held by 33 FIIs

DII

58.18%

Held by 22 DIIs

Promoter

15.86%

How big is Sagimet Biosciences, Inc.?

22-Jun-2025

As of Jun 18, Sagimet Biosciences, Inc. has a market capitalization of 211.04 million and reported net sales of 0.00 million with a net profit of -57.12 million over the last four quarters. The company's balance sheet shows shareholder's funds of 155.81 million and total assets of 160.26 million.

View full answer

What does Sagimet Biosciences, Inc. do?

22-Jun-2025

Sagimet Biosciences, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $18 million and a market cap of $211.04 million. Key financial metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -41.09%.

View full answer

Is Sagimet Biosciences, Inc. overvalued or undervalued?

25-Jun-2025

As of November 14, 2024, Sagimet Biosciences, Inc. is considered overvalued and has moved from a risky to a "does not qualify" valuation grade due to negative financial metrics, including a price-to-book ratio of 1.23, an ROE of -41.09%, and unfavorable comparisons to peers, despite a recent stock return of 142.32%.

View full answer

Is Sagimet Biosciences, Inc. technically bullish or bearish?

20-Sep-2025

As of August 1, 2025, Sagimet Biosciences, Inc. has a mildly bullish trend, supported by daily moving averages, but tempered by mildly bearish weekly indicators and a strong year-to-date return of 50.0%, significantly outperforming the S&P 500.

View full answer

Compare Sagimet Biosciences, Inc. with Similar Stocks

Emergent BioSolutions, Inc.Fusion Pharmaceuticals, Inc.Tenaya Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 197 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.98

Return on Equity

-48.36%

Price to Book

1.65

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-10 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-28.52%

6 Months

-35.62%

1 Year

6.88%

2 Years

-45.87%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Sagimet Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

31.60%

EBIT Growth (5y)

-213.04%

EBIT to Interest (avg)

-40.87

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.04

Sales to Capital Employed (avg)

0.02

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

80.04%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.23

EV to EBIT

-0.40

EV to EBITDA

-0.40

EV to Capital Employed

-4.70

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-41.09%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Bearish (Daily)

KST

Mildly Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 23 Schemes (18.81%)

Foreign Institutions

Held by 33 Foreign Institutions (7.09%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -28.40% vs -19.12% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.90",
          "val2": "-10.60",
          "chgp": "-12.26%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.40",
          "val2": "-8.10",
          "chgp": "-28.40%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs 0.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -63.44% vs 8.52% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "2.00",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-54.50",
          "val2": "-30.70",
          "chgp": "-77.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-45.60",
          "val2": "-27.90",
          "chgp": "-63.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-15,370.00%",
          "chgp": "1,537.00%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-11.90

-10.60

-12.26%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-10.40

-8.10

-28.40%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -28.40% vs -19.12% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

2.00

-100.00%

Operating Profit (PBDIT) excl Other Income

-54.50

-30.70

-77.52%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-45.60

-27.90

-63.44%

Operating Profit Margin (Excl OI)

0.00%

-15,370.00%

1,537.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -63.44% vs 8.52% in Dec 2023

All Annual Results

Company CV

About Sagimet Biosciences, Inc.

Sagimet Biosciences, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Sagimet Biosciences, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Sagimet Biosciences, Inc.?

Watch in Real-Time

What does Sagimet Biosciences, Inc. do?

Is Sagimet Biosciences, Inc. overvalued or undervalued?

Is Sagimet Biosciences, Inc. technically bullish or bearish?

Compare Sagimet Biosciences, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Sagimet Biosciences, Inc.

Company Coordinates